Provectus seeking Indian PV-10 API patent and says it is “more than a match” for skin cancer competitors
29-Jan-2015 - Provectus Biopharmacetuicals is seeking an Indian patent and partner for PV-10 and says it is 'more than a match' for skin cancer competitors like Merck & Co and Bristol-Myers Squibb.
News in brief
28-Jan-2015 - Johnson Matthey saw demand for ADHD APIs increase in the third quarter, while sales of its pain management ingredients and bulk opiates declined.
27-Jan-2015 - China has told Provectus Biopharmaceuticals it will grant a patent for the method used to make the API in its skin cancer drug candidate, PV-10.
23-Jan-2015 - BASF will spend €56m to increase production capacity for the excipient PVP by expanding existing plants and introducing manufacturing capabilities at its facility in Shanghai, China.
22-Jan-2015 - Biopharma outsourcing growth has helped to boost the bottom line of Lonza, the world’s largest manufacturer of drug ingredients, though a topsy-turvy Swiss franc has caused the company to hold off on making any projections for 2015.
20-Jan-2015 - Sea snail venom could yield new human insulin analogues or painkillers, according to a University of Utah scientist.
20-Jan-2015 - In order to align more closely with ICH’s Q3D guideline for elemental impurities, USP has pushed back until 2018 when its chapter on elemental impurities will apply to industry.
14-Jan-2015 - Synthetic paclitaxel production methods can support expanding market and new indications according to market analysis group.
Ingredients: Featured news
John Giannone - incoming IPEC-Americas chairman
Irwin Silverstein, COO and VP of the International Pharmaceutical Excipients...
in-Pharmatechnologist.com presents a roundup of news in the fine chemicals sector, beginning with Johnson Matthey which has started a review of its active pharmaceutical ingredient (API) business after competition in the UK impacted its third quarter margins.